Lipid management among individuals with inflammatory arthritis in the national REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.

Abstract

Objective Hyperlipidemia guidelines do not currently identify inflammatory arthritis (IA) as a cardiovascular disease (CVD) risk factor. We compared hyperlipidemia treatment of individuals with and without IA (rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis) in a large national cohort. Methods Participants from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study were classified as having IA (without diabetes or hypertension); diabetes (but no IA); hypertension (but no diabetes or IA); or no IA, diabetes, or hypertension. Multivariable logistic regression models examined the odds of medical treatment among those with hyperlipidemia. Results Thirty-nine participants had IA, 5423 had diabetes, 7534 had hypertension, and 5288 had no diabetes, hypertension, or IA. The fully adjusted odds of treatment were similar between participants with IA and those without IA, hypertension, or diabetes. Participants with diabetes and no IA and participants with hypertension and no IA were twice as likely to be treated for hyperlipidemia as those without IA, diabetes, or hypertension. Conclusion Despite their higher CVD risk, patients with IA were as likely to be treated for hyperlipidemia as those without diabetes, hypertension, or IA. Lipid guidelines should identify IA as a CVD risk factor to improve CVD risk optimization in IA.

• Authors: Iris Navarro-Millán, Christopher M Gamboa, Jeffrey R Curtis, Monika M Safford
• Journal: The Journal of international medical research (J Int Med Res) Vol. 46 Issue 1 Pg. 62-69 (Jan 2018) ISSN: 1473-2300 [Electronic] England
• PMID: 28701103 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antirheumatic Agents
• Hypolipidemic Agents
• Immunosuppressive Agents

Topics

• Aged
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Arthritis, Psoriatic (drug therapy, ethnology, metabolism, physiopathology)
• Arthritis, Rheumatoid (drug therapy, ethnology, metabolism, physiopathology)
• Black People
• Cohort Studies
• Diabetes Mellitus (drug therapy, ethnology, metabolism, physiopathology)
• Female
• Humans
• Hyperlipidemias (drug therapy, ethnology, metabolism, physiopathology)
• Hypertension (drug therapy, ethnology, metabolism, physiopathology)
• Hypolipidemic Agents (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Male
• Middle Aged
• Multivariate Analysis
• Odds Ratio
• Risk Factors
• Spondylitis, Ankylosing (drug therapy, ethnology, metabolism, physiopathology)
• Stroke (drug therapy, ethnology, metabolism, physiopathology)
• United States
• White People